These kits concentrate urine proteins while simultaneously removing salts, urea, and other urine contaminants. There is no molecular weight cut-off and therefore the columns capture total urinary proteins and peptides of all sizes making them ideal for biomarker discovery work, differential expression of proteins in various diseases, or other diagnostic research. The columns are convenient, rapid and easy to use and thus offer significant time savings over classic dialysis protocols. The resulting high-quality protein sample is concentrated and free from the original sample salts, thus preparing the sample conveniently for downstream proteomic applications including SDS-PAGE, 2D Gels, MALDI-TOF, LC/MS, LC/MS/MS, whole protein mass spectrometry, western blotting, protein microarrays, and more.
ProteoSpin™ Urine Protein Concentration Micro Kit
Each spin column is able to concentrate and desalt up to 200 μg of urine proteins. Twelve samples can be processed in 20 minutes.
ProteoSpin™ Urine Protein Concentration Midi Kit
The ProteoSpin™ Urine Protein Concentration Midi Kit provides a fast and simple procedure for concentrating dilute solutions of urine proteins from 1 to 5 mL inputs of urine. Each mini spin column is able to concentrate and desalt up to 3 mg of urine proteins in 30 minutes.
ProteoSpin™ Urine Protein Concentration Maxi Kit
The ProteoSpin™ Urine Protein Concentration Maxi Kit provides a fast and simple procedure for concentrating dilute solutions of urine proteins from 2 to 20 mL inputs of urine. Each maxi spin column is able to concentrate and desalt up to 4 mg of urine proteins in 45 minutes.
Figure 1 / 7
Click for expanded view
| Kit Specifications | |
| Maximum Urine Input Volume | 20 mL |
| Maximum Recovered Protein | 4 mg |
| Minimum Elution Volume | 2 mL |
| Time to Process 4 Samples | 45 minutes |
Storage Conditions
All solutions should be kept tightly sealed and stored at room temperature. Once opened, the solution should be stored at 4°C. This kit is stable for 2 years after the date of shipment.
| Component | Cat. 17400 (25 preps) | Cat. 52300 (10 preps) | Cat. 21600 (4 preps) |
|---|---|---|---|
| Wash Solution C | 60 mL | 60 mL | 130 mL |
| Binding Buffer A | 4 mL | 4 mL | 8 mL |
| Elution Buffer C | 8 mL | 30 mL | 30 mL |
| Protein Neutralizer | 4 mL | 4 mL | 4 mL |
| Micro Spin Columns | 25 | – | – |
| Midi Spin Columns (assembled with collection tubes) | – | 10 | – |
| Maxi Spin Columns (assembled with collection tubes) | – | – | 4 |
| Collection Tubes | 25 | – | – |
| Elution Tubes (1.7 mL) | 25 | – | – |
| Midi Elution Tubes | – | 10 | – |
| Elution Tubes (50 mL) | – | – | 4 |
| Product Insert | 1 | 1 |
| Clone | IHC411 |
| Source | Rabbit Monoclonal |
| Positive Control | Tonsil, Lung Adenocarcinoma |
| Dilution Range | 1:200 |
Programmed Death-Ligand 1 (PD-L1), also known as CD274 or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumor cells resistant to CD8 T cell-mediated lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumor aggressiveness and risk of death, and, in ovarian cancer, higher expression of this protein has lead to significantly poorer prognosis. PD-L1 has also been linked to systemic lupus erythematosus and cutaneous melanoma. When considered in adjunct with CD8 tumor-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.
